Medical treatment of rheumatoid arthritis (I): Nonsteroidal anti-inflammatory drugs, disease modifying antirheumatic drugs and glucocorticoids

被引:0
|
作者
Koh, Eun-Mi [1 ]
机构
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med, Seoul, South Korea
来源
JOURNAL OF THE KOREAN MEDICAL ASSOCIATION | 2010年 / 53卷 / 10期
关键词
Rheumatoid arthritis; NSAIDs; DMARDs; Glucocorticoids; RECOMMENDATIONS; MANAGEMENT;
D O I
10.5124/jkma.2010.53.10.871
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The medical treatment of rheumatoid arthritis has been dramatically improved with the advances of newer disease-modifying antirheumatic drugs (DMARDs) and biologic agents during previous decades. To prevent joint damage, it is essential to start DMARD treatment early, especially within the first 3 months after diagnosis. Tight control of disease activity, and the thorough monitoring of the treatment's efficacy and the side effects of medications are also important. Nonsteroidal anti-inflammatory drugs (NSAIDs) are usually used to control pain and swelling of the joints. However, these drugs cannot alter the disease course of rheumatoid arthritis. It is therefore necessary to introduce DMARDs at the beginning of treatment, and, after achieving the effect of DMARDs, NSAIDs should be tapered as soon as possible. The main treatment should be DMARDs, which must be used wisely and appropriately. It is also important to adjust DMARD therapy during the course of treatment according to disease activity. Glucocorticoids have potent anti-inflammatory effects and can control inflammation dramatically. However, because of the diverse and serious side effects of glucocorticoids, the usage of glucocorticoids should be limited to low-dose oral therapy or intra-articular injection, unless otherwise indicated. Along with biologics, there are now various weapons available against rheumatoid arthritis, and it can be treated much more effectively than before.
引用
收藏
页码:871 / 879
页数:9
相关论文
共 50 条
  • [41] Cost-Effectiveness of Biologics Compared with Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
    Patel, Aarat M.
    Lupash, Daniel
    Chew, Douglas
    Levesque, Marc C.
    Moreland, Larry W.
    CURRENT RHEUMATOLOGY REPORTS, 2011, 13 (05) : 381 - 382
  • [42] Medicinal Plants and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) in Treatment of Arthritis: A Literature Review
    Kayani, Ruqaiya Rasheed
    Shamim, Rahat
    Munir, Safia Sultana
    Sultana, Misbah
    Nazir, Saeed Ur Rashid
    Riaz, Humayun
    Nazir, Taha
    Ali, Muhammad Maaz
    Islam, Azharul
    ALTERNATIVE THERAPIES IN HEALTH AND MEDICINE, 2022, 28 (07) : 58 - 64
  • [43] Socioeconomic impact of treatment with biological disease-modifying antirheumatic drugs in Japanese patients with rheumatoid arthritis
    Yamanaka, Hisashi
    Kishimoto, Mitsumasa
    Nishijima, Nobuo
    Yamashita, Katsuhisa
    Matsushima, Junnosuke
    O'Brien, Jacqueline
    Blachley, Taylor
    Eliot, Melissa
    Margolin, Zachary
    Dave, Swapna S.
    Tanaka, Yoshiya
    MODERN RHEUMATOLOGY, 2023, 34 (01) : 27 - 36
  • [44] Disease-modifying antirheumatic drugs other than methotrexate in rheumatoid arthritis and seronegative arthritis
    Nandi, Pradip
    Kingsley, Gabrielle H.
    Scott, David L.
    CURRENT OPINION IN RHEUMATOLOGY, 2008, 20 (03) : 251 - 256
  • [45] Mixed Treatment Comparison of the Treatment Discontinuations of Biologic Disease-Modifying Antirheumatic Drugs in Adults with Rheumatoid Arthritis
    Desai, Rishi J.
    Hansen, Richard A.
    Rao, Jaya K.
    Wilkins, Tania M.
    Harden, Elizabeth A.
    Yuen, Andrea
    Jonas, Daniel E.
    Roubey, Robert
    Jonas, Beth
    Gartlehner, Gerald
    Lux, Linda
    Donahue, Katrina E.
    ANNALS OF PHARMACOTHERAPY, 2012, 46 (11) : 1491 - 1505
  • [46] Machine Learning Prediction of Treatment Response to Biological Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
    Salehi, Fatemeh
    Lopera Gonzalez, Luis I.
    Bayat, Sara
    Kleyer, Arnd
    Zanca, Dario
    Brost, Alexander
    Schett, Georg
    Eskofier, Bjoern M.
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (13)
  • [47] Role of Nonsteroidal Anti-Inflammatory Drugs in Exacerbations of Inflammatory Bowel Disease
    Long, Millie D.
    Kappelman, Michael D.
    Martin, Christopher F.
    Chen, Wenli
    Anton, Kristen
    Sandler, Robert S.
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2016, 50 (02) : 152 - 156
  • [48] Methotrexate and non-steroidal anti-inflammatory drugs in rheumatoid arthritis treatment
    Bertin, P
    Carpentier, N
    Vergne, P
    Bonnet, C
    Bannwarth, B
    Dehais, J
    Treves, R
    THERAPIE, 1997, 52 (02): : 133 - 137
  • [49] Pharmacotherapeutic combination strategies with disease-modifying antirheumatic drugs in established rheumatoid arthritis
    van Riel, PLCM
    Haagsma, CJ
    Furst, DE
    BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 1999, 13 (04): : 689 - 700
  • [50] The Risk of Cardiovascular Events Associated With Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis
    Ozen, Gulsen
    Pedro, Sofia
    Michaud, Kaleb
    JOURNAL OF RHEUMATOLOGY, 2021, 48 (05) : 648 - 655